Article in Press
Jerzy P. Szaflarski, MD, PhD
Correspondence information about the author MD, PhD Jerzy P. Szaflarski
Email the author MD, PhD Jerzy P. Szaflarski,
Correspondence information about the author MD, PhD Jerzy P. SzaflarskiEmail the author MD, PhD Jerzy P. Szaflarski,
Article Info
Over the past five years, the lay press and families of children with catastrophic epilepsies popularized the use of cannabis and cannabinoids to treat seizures [1]. Many state legislatures have responded to the pressure from lay groups and have legalized medical cannabis, which is now available to a majority of people in the United States. Patients throughout the world are also obtaining and using cannabinoids to treat their epilepsy. There is an enormous dissociation between the widespread use of cannabis-based therapies to treat 
diverse epilepsies and our understanding about the efficacy and safety of different cannabinoids in treating different epilepsy syndromes.
